Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry PlatformTransaction marks one of the first clinical-stage oncology acquisitions sourced, evaluated, and executed through an AI-powered drug development platform
Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AINEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion.
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug DevelopmentNEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member.
Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 InhibitorCHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced the first patient has been dosed in the Company’s Phase 1b/2a clinical trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with abiraterone acetate, olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC), (P300-02-001, NCT06785636). Pocenbrodib is Pathos’ first clinical-stage asset in its pipeline.
Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug DevelopmentCHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding round. The Series C financing round was led by New Enterprise Associates (NEA) with participation from Revolution Growth and other existing insiders. This new capital infusion will enable Pathos to expand its team of world-class scientists and engineers, accelerate the development of its AI-powered drug development platform, and advance its clinical-stage pipeline of precision oncology therapeutics. This latest round, which also included its existing investors, Lightbank and Builders VC, was completed at a $600 million post money valuation, bringing the three-year-old company’s total funding to $102M.
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Brain-penetrant, PRMT5 InhibitorCHICAGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today the world-wide license of PRT811, a potent, selective, and orally bioavailable brain penetrant SAM-competitive PRMT5 inhibitor from Prelude Therapeutics.
